Cohance Lifesciences Limited — research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Cohance Lifesciences Limited, explained in plain English.

• ▪Cohance Lifesciences Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
• ▪Reported fundamentals show a net margin of 4.96%, debt to equity of 9.93.
• ▪Our transparent MaxGrade checklist scores it D (46/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 50.55% with a maximum drawdown of -69.06%.

Last traded values from 6 Oct 2026. Market closed.